me too.Dr. Waymack (Chairman of the Board of Directors and Chief Medical Officer): Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.
January 08, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that it has appointed Dr. Gil Ben-Menachem as Vice President Business Development. The appointment comes following Kitov’s recent announcement that the pivotal Phase III trial of its lead drug candidate KIT-302 successfully met its primary endpoint. A combination drug, KIT-302, simultaneously treats osteoarthritis pain as well as hypertension, which is a common side effect of non-steroidal anti-inflammatory (NSAID) drugs.
Dr. Ben-Menachem is a seasoned executive with over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries. He was most recently Head of Innovative Products at Dexcel Pharma, the second largest Israeli pharmaceutical company. Dr. Ben-Menachem previously served as Director of Business Development at Teva Pharmaceutical Industries, where he was responsible for business development efforts leading to partnering and acquisition deals valued at more than $500 million for late stage innovative drug candidates. Prior positions held by Dr. Ben-Menachem include serving as CEO of OphthaliX, a company that developed drugs in the ophthalmology space, and serving as Director of Business Development at Paramount Biosciences, a New York based merchant bank and biotechnology venture capital firm. Dr. Ben-Menachem received his Ph.D. from the Hebrew University, and MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the NIH.
"I am honored and delighted to take this position at Kitov," commented Dr. Gil Ben-Menachem, Kitov’s Vice President of Business Development. "With Kitov’s lead drug candidate, KIT-302, being prepared for NDA submission, the business development prospects awaiting Kitov are exciting. I Iook forward to facilitating the partnering of KIT-302 and to expanding Kitov’s pipeline”.
"Dr. Ben-Menachem has a very strong track record of performance in the industry and we believe his appointment will drive Kitov’s business development efforts towards achieving our strategic goals,” stated Kitov CEO Isaac Israel.
News 
Market Data 
Discover 
